Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$40.46 USD

40.46
655,511

-0.71 (-1.72%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $40.46 0.00 (0.00%) 5:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Tandem Diabetes (TNDM) for Now

by Zacks Equity Research

Investors are optimistic about Tandem Diabetes' (TNDM) t:slim X2 technology and greater use of Control-IQ technology.

Tandem Diabetes Care, Inc. (TNDM) Stock Jumps 6.5%: Will It Continue to Soar?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Retain Tandem Diabetes (TNDM) for Now

by Zacks Equity Research

Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.

Why Is Tandem Diabetes Care, Inc. (TNDM) Down 3.7% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Tandem Diabetes Care, Inc. (TNDM) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Tandem Diabetes (TNDM) Q3 Earnings Top Estimates, Sales View Up

by Zacks Equity Research

Tandem Diabetes (TNDM) reports better-than-expected revenues for third-quarter 2021 as strong domestic and international pump shipments drive the top line.

    Tandem Diabetes Care, Inc. (TNDM) Tops Q3 Earnings and Revenue Estimates

    by Zacks Equity Research

    Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 25.00% and 3.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Tandem Diabetes Care, Inc. (TNDM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    by Zacks Equity Research

    Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Here's Why You Should Retain Tandem Diabetes (TNDM) for Now

    by Zacks Equity Research

    Investors are optimistic about Tandem Diabetes (TNDM) owing to robust international pump shipments and product launches.

    Here's Why Tandem Diabetes Care, Inc. (TNDM) is a Strong Momentum Stock

    by Zacks Equity Research

    The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

    Tandem Diabetes (TNDM) Rides on Innovation Despite Cost Woes

    by Zacks Equity Research

    Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 insulin pumps by both new and existing users is encouraging.

    Tandem Diabetes Care, Inc. (TNDM) Up 3.2% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Merit Medical (MMSI) Soars to 52-Week High, Time to Cash Out?

    by Zacks Equity Research

    Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

    Here's Why You Should Invest In Tandem Diabetes (TNDM) Now

    by Zacks Equity Research

    Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 technology and international expansion of the Control-IQ technology add to the company's solid second-quarter performance.

    Tandem Diabetes (TNDM) Q2 Earnings Rise Y/Y, Sales View Up

    by Zacks Equity Research

    Tandem Diabetes (TNDM) reports better-than-expected revenues for second quarter 2021 on strong domestic and international pump shipments driving the top line.

    Tandem Diabetes Care, Inc. (TNDM) Surpasses Q2 Earnings and Revenue Estimates

    by Zacks Equity Research

    Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 175.00% and 19.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Will Tandem Diabetes Care, Inc. (TNDM) Report Negative Earnings Next Week? What You Should Know

    by Zacks Equity Research

    Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Debanjana Dey headshot

    Diabetes Space Thrives on CGM Devices in 2021: 3 Stocks in Focus

    by Debanjana Dey

    CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.

    Tandem (TNDM) Presents Data Backing Control-IQ Technology

    by Zacks Equity Research

    Data presented at the ATTD conference demonstrates Tandem Diabetes Care's (TNDM) Control-IQ technology's ability to make a positive and sustained impact on diabetes care.

    Why Is Tandem Diabetes Care, Inc. (TNDM) Up 0.2% Since Last Earnings Report?

    by Zacks Equity Research

    Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now

    by Zacks Equity Research

    Investors continue to be optimistic about Tandem Diabetes (TNDM) on strong quarterly results and robust pump sales.

    Tandem (TNDM) Global Growth Strong, Costs Continue to Rise

    by Zacks Equity Research

    Tandem Diabetes (TNDM) is witnessing high international demand for the t:slim X2 pump.

    Tandem Diabetes (TNDM) Q1 Net Loss Narrows, Guidance Up

    by Zacks Equity Research

    Tandem Diabetes' (TNDM) strong international and domestic pump sales and shipment boosted the first-quarter top line.

    Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 53.33% and 14.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    by Zacks Equity Research

    Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.